Patient Square Capital leads Osanni Bio USD 190 million Series B round

  • Osanni Bio closed a USD 190 million Series B financing led by Patient Square Capital on June 23, 2026.
  • Osanni is a development-stage therapeutics platform focused on reinventing drug discovery and development.
  • Funding earmarked to advance multiple pipeline programs, including in ophthalmology and cardiology, while scaling its discovery process.
  • Existing investors Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund participated in the round.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Patient Square Capital LP published the original content used to generate this news brief on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.